Patients have different response to different treatment modalities, and sore/pain medicine is
no exception. In our experience, low-level laser (LLL), ultrasound, and prolotherapy can
reduce sore /pain through different genetic pathway. Whether the therapeutic effect is
controlled by the genetic variants of those sore /pain related genes or not, is still in
debate. The aims of this study are (1) To find genetic SNPs which can determine the response
of sore /pain treatment modalities. (2) To find possible metabolomics and proteomic markers
of sore /pain. (3) To determine the algorithm of precision medicine for sore /pain control
via the genetic markers. Investigators will recruit 80 myofascial pain patients from
Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
Bei-Hu Branch in 2021 and 2022. The participants will receive LLL, ultrasound, and
prolotherapy, and the therapeutic effect will be recorded. The blood and urine samples from
the first, the second, and the third visits will be analyzed by next generation sequencing,
and mass spectrometry to find the possible biomarker in 2023 and 2024. Investigators expect
to develop the individualized treatment plan by means of these biomarkers. Hopefully, the
results will be widely applied in the field of sore /pain medicine.
Phase:
N/A
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
Ministry of Science and Technology, Taiwan National Health Research Institutes, Taiwan